Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020

							Ovarian Cancer Therapeutics - Global Drug Forecasts
and Treatment Analysis 2020

Aarkstore Enterprise
Tel: +919272852585 / +918149852585
Telefax No: (+91) 2224169996
E-mail: contact@aarkstore.com
Website: http://www.aarkstore.com
Ovarian Cancer Therapeutics - Global Drug Forecasts
and Treatment Analysis 2020

Date:      29 February 2012


Pages: 438

Price:     US$ $6,995.00


Company announces 20% discount on this report.
Discount till 30th Nov. 2012

Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020

Summary

“Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020”. The report is an essential
source of information and analysis on the global ovarian cancer therapeutics market. The report provides
comprehensive information on ovarian cancer, highlighting the treatment guidelines. It identifies and analyses
the key trends shaping and driving the global ovarian cancer therapeutics market. It analyses the treatment
usage patterns in the global ovarian cancer therapeutics market. The report also provides insights into the
competitive landscape and the emerging players expected to significantly alter the positions of the existing
market leaders. The report provides valuable insights into the pipeline products within the global ovarian
cancer sector. It quantifies the unmet need in the global ovarian cancer therapeutics market as well as in the
individual markets such as the US and the top five countries in Europe, highlighting the opportunity for future
players.

This report is built using data and information sourced from proprietary databases, primary and secondary
research and in-house analysis by Company’s team of industry experts.

The ovarian cancer therapeutics market grew at a Compound Annual Growth Rate (CAGR) of only 1.0%
between 2002 and 2011. The patent expiries of major branded products, such as Taxol (paclitaxel), Paraplatin
(carboplatin), Gemzar (gemcitabine), Hycamtin (topotecan hydrochloride) and the subsequent launch of
generics, have acted as restraining factors to the market. The introduction of new and promising therapies
such as Avastin (bevacizumab), AMG 386, EC145, Farletuzumab (MORAb-003), Karenitecin (BNP1350),
OPAXIO (paclitaxel poliglumex), OPT-821, Paclical (paclitaxel), Vargatef (BIBF 1120) and Votrient (pazopanib)
are expected to drive the market from 2011–2020.
 In 2011, the ovarian cancer therapeutics markets in key countries (the US, the UK, Germany, France, Italy,
Spain, Japan, Brazil, Russia, India and China) were worth $736.7m collectively. The ovarian cancer
therapeutics market is expected to witness three-fold growth by 2020, reaching $2,352m at a CAGR of 13.8%.
This high growth rate is expected due to the strength of the pipeline candidates, which are anticipated to
change the treatment paradigm of ovarian cancer when launched.

Scope


The scope of the report includes -
 - An overview of ovarian cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and
treatment guidelines.
 - Annualized global ovarian cancer therapeutics market revenue, annual cost of therapy and treatment usage
patterns data by stage of the disease from 2002 to 2010, forecast for 10 years to 2020.
 - Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain,
Germany, France Japan and BRIC countries that include Brazil, Russia, India and China
- Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events.
 - Competitor assessment including drug launch analysis and drug sales forecasts.
 - Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM
activities, product positioning and drug sales forecast.
- Analysis of unmet need in the market and target product profile including opportunity for target product.
 - Technology trends analytic framework to assess strength of pipeline.
 - Pipeline analysis data providing a split by stage of the disease and line of therapy across different phases,
mechanisms of action being developed and emerging trends. The key classes of mechanism of action include
microtubule stabilizers, vascular endothelial growth factor receptor (VEGFR) inhibitors, immunomodulators,
folate receptor inhibitors, poly ADP ribose polymerase (PARP) inhibitors, topoisomerase inhibitors, interleukins,
mammalian target of rapamycin (mTOR) inhibitors and phosphatidylinositol-3-kinase (PI3K) inhibitors.
 - Clinical trials mapping of trials for ovarian cancer in different regions.
 - An overview of the most promising drugs’ including clinical study details, efficacy, safety, collaboration
agreements, marketing rights, and launch analysis and drug sales forcasts to 2020.
 - Analysis of the current and future market competition in the global ovarian cancer therapeutics market.
 - Company profiles including business description, financial overview and SWOT analysis. Key future market
players covered include F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Amgen Inc, AstraZeneca PLC,
Boehringer Ingelheim GmbH, Oasmia Pharmaceutical AB, Endocyte, Inc, BioNumerik Pharmaceuticals, Inc,
Eisai Inc., Cell Therapeutics, Inc, and Menarini Group,
 - Analysis of licensing agreements during 2008-2010 in the ovarian cancer therapeutics market. M&A analysis
which includes M&A deals by size and geography.
 - Strategic assessment of the market through market impact analysis, future market scenario and company
analysis.
 - Direct quotes from key opinion leaders (KOL) or physicians in the ovarian cancer therapeutics market.

Reasons to buy


The report will enhance your decision making capability. It will allow you to -
- Develop business strategies and perform superior market quantification analysis by
 - Understanding the trends shaping and driving the global ovarian cancer therapeutics market.
 - Understanding treatment preferences of physicians in disease state and across treatment flow.
 - Accessing market sizing, forecasts and quantified growth opportunities in the global ovarian cancer
therapeutics market till 2020.
 - Quantifying patient population in the global ovarian cancer market to better design product pricing & launch
plans.
 - Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the
competitive landscape by
 - performing benchmarking analysis and growth opportunities against currently marketed products
- Identifying market entry points based on safety, efficacy, and pricing parameters.
- Assessing competitiveness of products in market by understanding the strength and weakness of current
competition.
 - Develop and design your in-licensing and out-licensing strategies by
 - Taking a comprehensive look of at the disease pipeline and identifying most promising paradigm shifting
products.
 - Assessing strength of pipeline bases on first in class, me-too, generic and lifecycle management of products.
 - Track drug sales in the global ovarian cancer therapeutics market from 2002 to 2020
 - Identify the emerging players with potentially strong product portfolios and create effective counter-
strategies to gain a competitive advantage.
 - Organize your sales and marketing efforts by identifying the market categories and segments that present
the best opportunities for consolidation, investments and strategic partnerships.
 - What’s the next big thing in the global ovarian cancer therapeutics market landscape? Identify, understand
and capitalize.

Keywords

Market forecast, revenues, unmet need, drivers, barriers, pharma, clinical trials, marketed products, pipeline,
promising drugs, future players, key companies, strategic competitor assessment, market characterization,
implications for future market, mechanism of action, oncology, cancer, treatment guideline, target product
profile, clinician's endpoints, disease overview, colorectal cancer drug sales, US colorectal cancer market, UK
colorectal cancer market, France colorectal cancer market, Germany colorectal cancer market, Italy colorectal
cancer market, Spain colorectal cancer market, Japan colorectal cancer market, BRIC colorectal cancer market,
Brazil, Russia, India, China

Table of Contents :

1.1 List of Tables 8
1.2 List of Figures 11
2 Ovarian Cancer Therapeutics - Disease Overview 16
2.1 Overview 16
2.1.1 Types of Ovarian Cancer 16
2.2 Staging and Treatment of Ovarian Cancer 17
2.2.1 Stage I 21
2.2.2 Stage IA 21
2.2.3 Stage IB 21
2.2.4 Stage IC 21
2.2.5 Stage II 21
2.2.6 Stage IIA 21
2.2.7 Stage IIB 21
2.2.8 Stage IIC 21
2.2.9 Stage III 22
2.2.10 Stage IIIA 22
2.2.11 Stage IIIB 22
2.2.12 Stage IV 22
2.3 Epidemiology 22
2.4 Etiology 22
2.5 Symptoms 23
2.6 Risk Factors 23
2.7 Diagnosis 24
2.7.1 Physical Examination 24
2.7.2 Blood Tests 24
2.7.3 Human Chorionic Gonadotropin (hCG) Test 26
2.7.4 Ultrasound and CT Scans 26
2.7.5 Biopsy 26
2.8 Pathology 27
2.8.1 Grading 27
2.9 Prognosis 27
2.10 Treatment 28
2.10.1 Surgery 28
2.10.2 Chemotherapy 29
2.10.3 Radiation Therapy 29
2.11 Treatment Options by Stage 29
2.11.1 Stage IA 29
2.11.2 Stage IB 29
2.11.3 Stage IC 30
2.11.4 Stage IIA 30
2.11.5 Stage IIB, Stage IIC, Stage IIIA, Stage, IIIB, Stage IIIC, Stage IV 30
2.11.6 Treatment Follow-Up 30
2.12 Chemotherapy Regimens 32
2.13 Company In-Depth Report Guidance 33
3 Ovarian Cancer Therapeutics - Market Characterization 34
3.1 Global 34
3.1.1 Market Size 34
3.1.2 Drivers and Restraints 42
3.1.3 Forecasts 45
3.1.4 Drug Sales 54
3.2 The US 56
3.2.1 Market Size 56
3.2.2 Drivers and Restraints 63
3.2.3 Forecasts 66
3.2.4 Drug Sales 73
3.2.5 Pricing and Reimbursements 75
3.3 The UK 76
3.3.1 Market Size 76
3.3.2 Drivers and Restraints 84
3.3.3 Forecasts 87
3.3.4 Drug Sales 96
3.3.5 Pricing and Reimbursements 98
3.4 Germany 99
3.4.1 Market Size 99
3.4.2 Drivers and Restraints 107
3.4.3 Forecasts 110
3.4.4 Drug Sales 119
3.4.5 Pricing and Reimbursements 121
3.5 France 122
3.5.1 Market Size 122
3.5.2 Drivers and Restraints 130
3.5.3 Forecasts 132
3.5.4 Drug Sales 141
3.5.5 Pricing and Reimbursements 143
3.6 Italy 144
3.6.1 Market Size 144
3.6.2 Drivers and Restraints 152
3.6.3 Forecasts 155
3.6.4 Drug Sales 164
3.6.5 Pricing and Reimbursements 166
3.7 Spain 167
3.7.1 Market Size 167
3.7.2 Drivers and Restraints 175
3.7.3 Forecasts 178
3.7.4 Drug Sales 187
3.7.5 Pricing and Reimbursements 189
3.8 Japan 190
3.8.1 Market Size 190
3.8.2 Drivers and Restraints 198
3.8.3 Forecasts 201
3.8.4 Drug Sales 210
3.8.5 Pricing and Reimbursements 212
3.9 Brazil 213
3.9.1 Market Size 213
3.9.2 Patient Volume 216
3.9.3 Drivers and Restraints 220
3.9.4 Impact on the Market 222
3.9.5 Forecasts 223
3.9.6 Future Impact 229
3.10 Russia 230
3.10.1 Market Size 230
3.10.2 Drivers and Restraints 236
3.10.3 Impact on the Market 238
3.10.4 Forecasts 239
3.10.5 Future Impact 245
3.11 India 246
3.11.1 Market Size 246
3.11.2 Drivers and Restraints 253
3.11.3 Impact on the Market 255
3.11.4 Forecasts 256
3.11.5 Future Impact 263
3.12 China 264
3.12.1 Market Size 264
3.12.2 Drivers and Restraints 271
3.12.3 Impact on the Market 273
3.12.4 Forecasts 274
3.12.5 Future Impact 280
3.13 Key Takeaway 280
4 Ovarian Cancer Therapeutics - Opportunity and Unmet Need 281
4.1 Unmet Need 281
4.2 First-Line Treatment of Loco-Regional and Advanced/Metastatic Setting 282
4.3 Second-Line Treatment of Loco-Regional and Advanced/Metastatic Setting 283
4.4 Key Takeaway 283
5 Ovarian Cancer Therapeutics - Competitive Assessment 284
5.1 Strategic Competitor Assessment 284
5.1.1 Benchmarking 284
5.1.2 Current Competitor Assessment 292
5.1.3 Chemotherapy 293
6 Ovarian Cancer Therapeutics - Strategic Assessment 294
6.1 Key Events Impacting the Future Market 294
6.2 Market Impact Analysis 295
6.3 Future Market Scenario 296
7 Product Profiles for the Major Marketed Products in the Ovarian Cancer Market 297
7.1.1 Carboplatin 297
7.1.2 Cisplatin 304
7.1.3 Paclitaxel 308
7.1.4 Altretamine 314
7.1.5 Hycamtin (topotecan hydrochloride) 317
7.1.6 Gemzar (gemcitabine) 322
7.1.7 Yondelis (trabectedin) 326
7.1.8 Doxil (doxorubicin Hcl liposome injection) 331
7.2 Partners in Commercialization 336
7.2.1 Taj Pharmaceuticals Enters Into License Agreement with AstraZeneca Pharmaceuticals for Gemcitabine
HCI 336
7.2.2 APP Pharmaceuticals Enters Into Licensing Agreement with Teva Pharmaceutical for Gemcitabine HCI 336
7.3 Key Takeaway 336
8 Ovarian Cancer - Pipeline Assessment 337
8.1 Overview 337
8.2 Pipeline Analysis by Phase of Development 337
8.3 Pipeline by Mechanism of Action 338
8.4 Pipeline by Line of Therapy 339
8.5 Strategic Pipeline Assessment 340
8.5.1 Technology Trends Analytic Framework 340
8.6 Ovarian Cancer Pipeline – Pipeline by Clinical Phases of Development 342
8.6.1 Ovarian Cancer – Pre-Registration Clinical Pipeline 342
8.6.2 Ovarian Cancer – Phase III of the Clinical Pipeline 343
8.6.3 Ovarian Cancer – Phase II of the Clinical Pipeline 344
8.6.4 Ovarian Cancer – Phase I of the Clinical Pipeline 348
8.6.5 Ovarian Cancer – Preclinical Pipeline 350
8.6.6 Ovarian Cancer – Discovery Stage Pipeline 351
8.7 Most Promising Drug Profiles 351
8.7.1 Avastin (bevacizumab) 351
8.7.2 Paclical (paclitaxel) 354
8.7.3 Votrient (pazopanib) 355
8.7.4 Farletuzumab (MORAb-003) 357
8.7.5 Karenitecin (BNP 1350) 359
8.7.6 Opaxio (xyotax, CT-2103) 361
8.7.7 AMG 386 364
8.7.8 EC-145 365
8.7.9 Recentin (cediranib, AZD2171) 367
8.7.10 Vargatef (BIBF 1120) 368
8.8 Partners in Research and Development 370
8.8.1 Licensing Agreements 370
8.8.2 Co-development Agreements 372
8.9 Key Takeaway 375
9 Ovarian Cancer Therapeutics - Clinical Trials Mapping 376
9.1 Clinical Trials 376
9.1.1 Clinical Trials by Status 376
9.1.2 Clinical Trials by Country 377
9.1.3 Clinical Trials by Phase 378
9.1.4 Clinical Trials by Sponsor Type 379
9.1.5 Clinical Trials – Leading Sponsors 380
9.1.6 Clinical Trials – Leading Company Sponsors by Phase 381
9.2 Patient Recruitment 382
10 Ovarian Cancer Therapeutics - Future Market Players 383
10.1 F. Hoffmann-La Roche Ltd. 383
10.1.1 Business Description 383
10.1.2 Financial Overview 383
10.1.3 SWOT Analysis 384
10.2 Menarini Group 389
10.2.1 Business Description 389
10.2.2 Financial Overview 389
10.2.3 SWOT Analysis 390
10.3 GlaxoSmithKline plc. 394
10.3.1 Business Description 394
10.3.2 Financial Overview 394
10.3.3 SWOT Analysis 395
10.4 Eisai Inc., 400
10.4.1 Business Description 400
10.4.2 Financial Overview 401
10.4.3 SWOT Analysis 401
10.5 Cell Therapeutics, Inc. 404
10.5.1 Business Description 404
10.5.2 Financial Overview 404
10.5.3 SWOT Analysis 405
10.6 Amgen Inc. 408
10.6.1 Business Description 408
10.6.2 Financial Overview 409
10.6.3 SWOT Analysis 410
10.7 AstraZeneca PLC 414
10.7.1 Business Description 414
10.7.2 Financial Overview 415
10.7.3 SWOT Analysis 415
10.8 Boehringer Ingelheim GmbH 419
10.8.1 Business Description 419
10.8.2 Financial Overview 419
10.8.3 SWOT Analysis 420
10.9 Oasmia Pharmaceutical AB 424
10.9.1 Business Description 424
10.9.2 Financial Overview 424
10.10 Endocyte, Inc. 424
10.10.1 Business Description 424
10.11 BioNumerik Pharmaceuticals, Inc. 424
10.11.1 Business Description 424
11 Ovarian Cancer Therapeutics - M&A Analysis 425
11.1 Key Highlights 425
11.1.1 M&A Agreements by Phase of Development 425
12 Ovarian Cancer Therapeutics - Expert Opinion 427
12.1 Important Data and Analysis from Key Opinion Leaders (KOLs) 427
12.1.1 Treatment Options (Surgery/Chemotherapy) 427
12.1.2 Treatment Options by Stage 427
12.1.3 Number of Chemotherapy Cycles 428
12.1.4 Future Therapies for Ovarian Cancer Treatment 428
12.1.5 Future Growth Rate of the Ovarian Cancer Market 428
12.1.6 Current Unmet Needs for Ovarian Cancer Treatment 428
12.1.7 What Ideal Features are Required in a New Drug 428
12.1.8 Past Patient Trends in Ovarian Cancer 428
12.1.9 Referral Pathway 428
13 Ovarian Cancer Therapeutics - Appendix 429
13.1 Definitions 429
13.2 Acronyms 429
13.3 Research Methodology 432
13.3.1 Coverage 433
13.3.2 Secondary Research 433
13.3.3 Forecasting 433
13.3.4 Primary Research 435
13.3.5 Expert Panel Validation 436
13.4 Contact Us 436
13.5 Disclaimer 436
13.6 Sources 436
1.1 List of Tables

Table   1: Ovarian Cancer, AJCC TNM and FIGO Staging System 17
Table   2: Ovarian Cancer, Classification and Treatment Protocol Stages 18
Table   3: Ovarian Cancer Stages I, II & III 20
Table   4: Ovarian Cancer Stage IV 21
Table   5: Ovarian Cancer, Classification of Ovarian Cancer, 2011 27
Table   6: Ovarian Cancer Five-Year Survival Rates 27
Table   7: Ovarian Cancer Chemotherapy Regimens 32
Table   8:Ovarian Cancer Therapeutics Market, Global, Sales Value ($m) by Country, 2002–2011 36
Table 9: Ovarian Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2002–2011 38
Table 10: Ovarian Cancer Therapeutics Market, Global, Patient Volume, 2002–2011 40
Table 11: Ovarian Cancer Therapeutics Market, Global, Treatment Usage Patterns, 2002–2011 41
Table 12: Ovarian Cancer Therapeutics Market, Global, Sales Value ($m), 2011–2020 45
Table 13: Ovarian Cancer Therapeutics Market, Global, Sales Value ($m), 2011–2020 47
Table 14: Ovarian Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2011–2020 48
Table 15: Ovarian Cancer Therapeutics Market, Global, Patient Volume, 2011–2020 50
Table 16: Ovarian Cancer Therapeutics Market, Global, Treatment Usage Patterns, 2011-2020 52
Table 17: Ovarian Cancer Therapeutics Market, Top Seven Countries, Drug Sales ($m), 2002–2011 54
Table 18: Ovarian Cancer Therapeutics Market, Top Seven Countries, Drug Sales ($m), 2011–2020 55
Table 19: Ovarian Cancer Therapeutics Market, The US, Sales Value ($m), 2002–2011 56
Table 20: Ovarian Cancer Therapeutics Market, The US, Annual Cost of Therapy ($), 2002–2011 58
Table 21: Ovarian Cancer Therapeutics Market, The US, Patient Volume, 2002–2011 60
Table 22: Ovarian Cancer Therapeutics Market, The US, Treatment Usage Patterns, 2002–2011 61
Table 23: Ovarian Cancer Therapeutics Market, The US, Sales Value ($m), 2011–202066
Table 24: Ovarian Cancer Therapeutics Market, The US, Annual Cost of Therapy ($), 2011–2020 68
Table 25: Ovarian Cancer Therapeutics Market, The US, Patient Volume, 2011–2020 70
Table 26: Ovarian Cancer Therapeutics Market, The US, Treatment Usage Patterns, 2011–2020 71
Table 27: Ovarian Cancer Therapeutics Market, The US, Drug Sales ($m), 2002–2011 73
Table 28: Ovarian Cancer Therapeutics Market, The US, Drug Sales ($m), 2011–2020 74
Table 29: Ovarian Cancer Therapeutics Market, The UK, Sales Value ($m), 2002–2011 76
Table 30: Ovarian Cancer Therapeutics Market, The UK, Annual Cost of Therapy ($), 2002–2011 78
Table 31: Ovarian Cancer Therapeutics Market, The UK, Patient Volume, 2002–2011 80
Table 32: Ovarian Cancer Therapeutics Market, The UK, Treatment Usage Patterns, 2002–2011 82
Table   33:   Ovarian   Cancer   Therapeutics   Market,   The UK, Sales Value ($m), 2011–2020 87
Table   34:   Ovarian   Cancer   Therapeutics   Market,   the UK, Annual Cost of Therapy ($),2011–2020 89
Table   35:   Ovarian   Cancer   Therapeutics   Market,   The UK, Patient Volume, 2011–2020 91
Table   36:   Ovarian   Cancer   Therapeutics   Market,   The UK, Treatment Usage Patterns, 2011–2020 93
Table   37:   Ovarian   Cancer   Therapeutics   Market,   The UK, Drug Sales ($m), 2002–2011 96
Table   38:   Ovarian   Cancer   Therapeutics   Market,   The UK, Drug Sales ($m), 2011–2020 97
Table   39:   Ovarian   Cancer   Therapeutics   Market,   Germany, Sales Value ($m), 2002–2011 99
Table   40:   Ovarian   Cancer   Therapeutics   Market,   Germany, Annual Cost of Therapy ($), 2002–2011 101
Table   41:   Ovarian   Cancer   Therapeutics   Market,   Germany, Patient Volume, 2002–2011 103
Table   42:   Ovarian   Cancer   Therapeutics   Market,   Germany, Treatment Usage Patterns, 2002–2011 105
Table   43:   Ovarian   Cancer   Therapeutics   Market,   Germany, Sales Value ($m), 2011–2020 110
Table   44:   Ovarian   Cancer   Therapeutics   Market,   Germany, Annual Cost of Therapy ($), 2011–2020 112
Table   45:   Ovarian   Cancer   Therapeutics   Market,   Germany, Patient Volume, 2011–2020 114
Table   46:   Ovarian   Cancer   Therapeutics   Market,   Germany, Treatment Usage Patterns, 2011–2020 116
Table   47:   Ovarian   Cancer   Therapeutics   Market,   Germany, Drug Sales ($m), 2002–2011 119
Table   48:   Ovarian   Cancer   Therapeutics   Market,   Germany, Drug Sales ($m), 2011–2020 120
Table   49:   Ovarian   Cancer   Therapeutics   Market,   France, Sales Value ($m), 2002–2011 122
Table   50:   Ovarian   Cancer   Therapeutics   Market,   France, Annual Cost of Therapy ($), 2002–2011 124
Table   51:   Ovarian   Cancer   Therapeutics   Market,   France, Patient Volume, 2002–2011 126
Table   52:   Ovarian   Cancer   Therapeutics   Market,   France, Treatment Usage Patterns, 2002–2011 128
Table   53:   Ovarian   Cancer   Therapeutics   Market,   France, Sales Value ($m), 2011–2020 132
Table   54:   Ovarian   Cancer   Therapeutics   Market,   France, Annual Cost of Therapy ($), 2011–2020 134
Table   55: Ovarian Cancer Therapeutics Market, France, Patient Volume, 2011–2020 136
Table   56: Ovarian Cancer Therapeutics Market, France, Treatment Usage Patterns, 2011–2020 138
Table   57: Ovarian Cancer Therapeutics Market, France, Drug Sales ($m), 2002–2011 141
Table   58: Ovarian Cancer Therapeutics Market, France, Drug Sales ($m), 2011–2020 142
Table   59: Ovarian Cancer Therapeutics Market, Italy, Sales Value ($m), 2002–2011 144
Table   60: Ovarian Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2002–2011 146
Table   61: Ovarian Cancer Therapeutics Market, Italy, Patient Volume, 2002–2011 148
Table   62: Ovarian Cancer Therapeutics Market, Italy, Treatment Usage Patterns, 2002–2011 150
Table   63: Ovarian Cancer Therapeutics Market, Italy, Sales Value ($m), 2011–2020 155
Table   64: Ovarian Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2011–2020 157
Table   65: Ovarian Cancer Therapeutics Market, Italy, Patient Volume, 2011–2020 159
Table   66: Ovarian Cancer Therapeutics Market, Italy, Treatment Usage Patterns, 2011–2020 161
Table   67: Ovarian Cancer Therapeutics Market, Italy, Drug Sales ($m), 2002–2011 164
Table   68: Cancer Therapeutics Market, Italy, Drug Sales ($m), 2011–2020 165
Table   69: Ovarian Cancer Therapeutics Market, Spain, Sales Value ($m), 2002–2011 167
Table   70: Ovarian Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2002–2011 169
Table   71: Ovarian Cancer Therapeutics Market, Spain, Patient Volume, 2002–2011 171
Table   72: Ovarian Cancer Therapeutics Market, Spain, Treatment Usage Patterns, 2002–2011 173
Table   73: Ovarian Cancer Therapeutics Market, Spain, Sales Value ($m), 2011–2020 178
Table   74: Ovarian Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2011–2020 180
Table   75: Ovarian Cancer Therapeutics Market, Spain, Patient Volume, 2011–2020 182
Table   76: Ovarian Cancer Therapeutics Market, Spain, Treatment Usage Patterns, 2011–2020 184
Table   77: Ovarian Cancer Therapeutics Market, Spain, Drug Sales ($m), 2002–2011 187
Table   78: Ovarian Cancer Therapeutics Market, Spain, Drug Sales ($m), 2011–2020 188
Table   79: Ovarian Cancer Therapeutics Market, Japan, Drug Sales ($m), 2002-2011 190
Table   80: Ovarian Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002–2011 192
Table   81: Ovarian Cancer Therapeutics Market, Japan, Patient Volume, 2002–2011 194
Table   82: Ovarian Cancer Therapeutics Market, Japan, Treatment Usage Patterns, 2002–2011 196
Table   83: Ovarian Cancer Therapeutics Market, Japan, Sales Value ($m), 2011–2020 201
Table   84: Ovarian Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011–2020 203
Table   85: Ovarian Cancer Therapeutics Market, Japan, Patient Volume, 2011–2020 205
Table   86: Ovarian Cancer Therapeutics Market, Japan, Treatment Usage Patterns, 2011–2020 207
Table   87: Ovarian Cancer Therapeutics Market, Japan, Drug Sales ($m), 2002–2011 210
Table   88: Ovarian Cancer Therapeutics Market, Japan, Drug Sales ($m), 2011–2020 211
Table   89: Ovarian Cancer Therapeutics Market, Brazil, Sales Value ($m), 2002–2011 213
Table   90: Ovarian Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2002–2011 215
Table   91: Ovarian Cancer Therapeutics Market, Brazil, Patient Volume, 2002–2011 216
Table   92: Ovarian Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 2002–2011 218
Table   93: Ovarian Cancer Therapeutics Market, Brazil, Sales Value ($m), 2011–2020 223
Table   94: Ovarian Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2011–2020 225
Table   95: Ovarian Cancer Therapeutics Market, Brazil, Patient Volume , 2011–2020 226
Table   96: Ovarian Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 2011–2020 228
Table   97: Ovarian Cancer Therapeutics Market, Russia, Sales Value ($m), 2002–2011 230
Table   98: Ovarian Cancer Therapeutics Market, Russia, Annual Cost of Therapy ($), 2002–2011 231
Table   99: Ovarian Cancer Therapeutics Market, Russia, Patient Volume (Absolute), 2002–2011 232
Table   100: Ovarian Cancer Therapeutics Market, Russia, Treatment Usage Patterns, 2002–2011 234
Table   101: Ovarian Cancer Therapeutics Market, Russia, Sales Value ($m), 2011–2020 239
Table   102: Ovarian Cancer Therapeutics Market, Russia, Annual Cost of Therapy ($), 2011–2020 240
Table   103: Ovarian Cancer Therapeutics Market, Russia, Patient Volume (Absolute), 2011–2020 241
Table   104: Ovarian Cancer Therapeutics Market, Russia, Treatment Usage Patterns, 2011–2020 243
Table   105: Ovarian Cancer Therapeutics Market, India, Sales Value ($m), 2002–2011 246
Table   106: Ovarian Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2002–2011 248
Table   107: Ovarian Cancer Therapeutics Market, India, Patient Volume (Absolute), 2002–2011 249
Table   108: Ovarian Cancer Therapeutics Market, India, Treatment Usage Patterns, 2002–2011 251
Table   109: Ovarian Cancer Therapeutics Market, India, Sales Value ($m), 2011–2020 256
Table   110: Ovarian Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2011–2020 258
Table   111: Ovarian Cancer Therapeutics Market, India, Patient Volume (Absolute), 2011–2020 259
Table   112: Ovarian Cancer Therapeutics Market, India, Treatment Usage Patterns, 2011–2020 261
Table   113: Ovarian Cancer Therapeutics Market, China, Sales Value ($m), 2002–2011 264
Table   114: Ovarian Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 2002–2011 266
Table   115: Ovarian Cancer Therapeutics Market, China, Patient Volume (Absolute), 2002–2011 267
Table   116: Ovarian Cancer Therapeutics Market, China, Treatment Usage Patterns, 2002–2011 269
Table   117: Ovarian Cancer Therapeutics Market, China, Sales Value ($m), 2011–2020 274
Table   118: Ovarian Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 2011–2020 276
Table 119: Ovarian Cancer Therapeutics Market, China, Patient Volume (Absolute), 2011–2020 277
Table 120: Ovarian Cancer Therapeutics Market, China, Treatment Usage Patterns, 2011–2020 279
Table 121: Ovarian Cancer, Global, Clinical Endpoints – Approved Drugs, 2011 284
Table 122:Ovarian Cancer, Global, Clinical Endpoints for Benchmarking, First-Line Loco-Regional and
Advanced/Metastatic Setting, 2011 285
Table 123: Ovarian Cancer, Global, Clinical Endpoints for Benchmarking, Second-Line Loco-Regional and
Advanced/Metastatic Setting, 2011 285
Table 124:Ovarian Cancer Therapeutics , Global, Safety Profile of Approved Treatment in Loco-Regional and
Advanced/Metastatic Setting, 2011 292
Table 125:Ovarian Cancer Therapeutics Market, Global, Carboplatin, Incidence of Adverse Effects NCIC Study,
2011 298
Table 126:Ovarian Cancer Therapeutics Market, Global, Carboplatin, Incidence of Adverse Effects SWOG Study,
2011 299
Table 127:Ovarian Cancer Therapeutics Market, Global, Carboplatin, Overview of Pivotal Trials, 2011 300
Table 128:Ovarian Cancer Therapeutics Market, Global, Carboplatin, Progression Free Survival, 2011 301
Table 129: Ovarian Cancer Therapeutics Market, Global, Carboplatin, Overall Survival, 2011 301
Table 130:Ovarian Cancer Therapeutics Market, Global, Paclitaxel, Incidence of Adverse Effects in the First-Line
Treatment, 2011 309
Table 131:Ovarian Cancer Therapeutics Market, Global, Paclitaxel Incidence of Adverse Effects in the Second-
Line Treatment, 2011 310
Table 132:Ovarian Cancer Therapeutics Market, Global, Altretamine, Incidence of Adverse Effects, 2011 315
Table 133:Ovarian Cancer Therapeutics, Hycamtin, Incidence of Adverse Effects, 2011 318
Table 134: Ovarian Cancer Therapeutics , Gemzar, Incidence of Adverse Effects, 2011 323
Table 135:Ovarian Cancer Therapeutics Market, Global, Yondelis, Incidence of Adverse Effects, 2011 327
Table 136: Ovarian Cancer Therapeutics Market, Global, Doxil, Incidence of Adverse Effects, 2011 332
Table 137: Ovarian Cancer, Global, Pipeline by Line of Therapy, 2011 339
Table 138: Ovarian Cancer Pipeline, Pre-Registration, 2011 342
Table 139: Ovarian Cancer Pipeline, Phase III, 2011 343
Table 140: Ovarian Cancer Pipeline, Phase II, 2011 344
Table 141: Ovarian Cancer Pipeline, Phase I, 2011 348
Table 142: Ovarian Cancer Pipeline, Prelinical, 2011 350
Table 143: Ovarian Cancer Pipeline, Discovery, 2011 351
Table 144: Ovarian Cancer, Global, Licensing Agreements, 2009–2011 372
Table 145: Ovarian Cancer, Global, Co-development Agreements, 2009–2011 374
Table 146: Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Status, March 2011 376
Table 147: Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Country, March 2011 377
Table 148: Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Phase, March 2011 378
Table 149:Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, March 2011 379
Table 150:Ovarian Cancer Therapeutics Market, Global, Clinical Trials, Leading Sponsors, March 2011 380
Table 151:Ovarian Cancer Therapeutics Market, Global, Clinical Trials, Leading Company Sponsors, March 2011
381
Table 152:Ovarian Cancer Therapeutics Market, Global, Clinical Trials, Average Number of Patients Recruited,
March 2011 382
Table 153: Ovarian Cancer, Global, M&A Deals by Geography, 2009–2011 426
Table 154: Ovarian Cancer Therapeutics Market, Global, Treatment Options by Stage, 2011 427

1.2 List of Figures

Figure 1: Ovarian Cancer, Treatment Algorithm, Stage I and II 31
Figure 2: Ovarian Cancer, Treatment Algorithm, Stage III and IV 31
Figure 3: Ovarian Cancer Therapeutics Market, Global, Sales Value ($m), 2002–2011 34
Figure 4: Ovarian Cancer Therapeutics Market, Global, Sales Value ($m) by Country, 2002–2011 36
Figure 5: Ovarian Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2002–2011 38
Figure 6: Ovarian Cancer Therapeutics Market, Global, Patient Volum 2002–2011 39
Figure   7: Ovarian Cancer Therapeutics Market, Global, Treatment Usage Patterns, 2002–2011 41
Figure   8: Ovarian Cancer Therapeutics Market, Global, Market Drivers and Restraints, 2011 42
Figure   9: Ovarian Cancer Therapeutics Market, Global, the Impact of Historical Events on the Market, 2011 44
Figure   10: Ovarian Cancer Therapeutics Market, Global, Sales Value ($m), 2011–2020 45
Figure   11: Ovarian Cancer Therapeutics Market, Global, Sales Value ($m) by Country, 2011–2020 46
Figure   12: Ovarian Cancer Therapeutics Market, Global, Annual Cost of Therapy ($),2011–2020 48
Figure   13: Ovarian Cancer Therapeutics Market, Global, Patient Volume, 2011–2020 50
Figure   14: Ovarian Cancer Therapeutics Market, Global, Treatment Usage Patterns, 2011–2020 52
Figure 15: Ovarian Cancer Therapeutics Market, Global, Future Market Drivers and Restraints, 2011–2020 53
Figure 16: Ovarian Cancer Therapeutics Market, Top Seven Countries, Drug Sales ($m), 2002-2020 54
Figure 17: Ovarian Cancer Therapeutics Market, The US, Sales Value ($m), 2002–2011 56
Figure 18: Ovarian Cancer Therapeutics Market, The US, Annual Cost of Therapy ($), 2002–2011 58
Figure   19:   Ovarian   Cancer   Therapeutics   Market,   The   US,   Patient Volume (absolute), 2002–2011 60
Figure   20:   Ovarian   Cancer   Therapeutics   Market,   The   US,   Treatment Usage Patterns, 2002–2011 61
Figure   21:   Ovarian   Cancer   Therapeutics   Market,   The   US,   Market Drivers and Restraints, 2011 63
Figure   22:   Ovarian   Cancer   Therapeutics   Market,   The   US,   The Impact of Historical Events on the Market, 2011
65
Figure   23:   Ovarian   Cancer   Therapeutics   Market,   The   US,   Sales Value ($m), 2011–2020 66
Figure   24:   Ovarian   Cancer   Therapeutics   Market,   The   US,   Annual Cost of Therapy ($),2011–2020 68
Figure   25:   Ovarian   Cancer   Therapeutics   Market,   The   US,   Patient Volume (Absolute), 2011–2020 70
Figure   26:   Ovarian   Cancer   Therapeutics   Market,   The   US,   Treatment Usage Patterns, 2011–2020 71
Figure   27:   Ovarian   Cancer   Therapeutics   Market,   The   US,   Future Market Drivers and Restraints, 2011–2020 72
Figure   28:   Ovarian   Cancer   Therapeutics   Market,   The   US,   Drug Sales ($m), 2002-2020 73
Figure   29:   Ovarian   Cancer   Therapeutics   Market,   The   UK,   Sales Value ($m), 2002–2011 76
Figure   30:   Ovarian   Cancer   Therapeutics   Market,   The   UK,   Annual Cost of Therapy ($)2002–2011 78
Figure   31:   Ovarian   Cancer   Therapeutics   Market,   The   UK,   Patient Volume (Absolute), 2002–2011 80
Figure   32:   Ovarian   Cancer   Therapeutics   Market,   The   UK,   Treatment Usage Patterns, 2002–2011 82
Figure   33:   Ovarian   Cancer   Therapeutics   Market,   The   UK,   Market Drivers and Restraints, 2011 84
Figure   34:   Ovarian   Cancer   Therapeutics   Market,   The   UK,   The Impact of Historical Events on the Market, 2011
86
Figure   35:   Ovarian   Cancer   Therapeutics   Market,   The UK, Sales Value ($m), 2011–2020 87
Figure   36:   Ovarian   Cancer   Therapeutics   Market,   The UK, Annual Cost of Therapy ($),2011–2020 89
Figure   37:   Ovarian   Cancer   Therapeutics   Market,   The UK, Patient Volume (Absolute), 2011–2020 91
Figure   38:   Ovarian   Cancer   Therapeutics   Market,   The UK, Treatment Usage Patterns, 2011–2020 93
Figure   39:   Ovarian   Cancer   Therapeutics   Market,   The UK, Future Market Drivers and Restraints, 2011–2020 95
Figure   40:   Ovarian   Cancer   Therapeutics   Market,   The UK, Drug Sales ($m), 2002-2020 96
Figure   41:   Ovarian   Cancer   Therapeutics   Market,   Germany, Sales Value ($m), 2002–2011 99
Figure   42:   Ovarian   Cancer   Therapeutics   Market,   Germany, Annual Cost of Therapy ($), 2002–2011 101
Figure   43:   Ovarian   Cancer   Therapeutics   Market,   Germany, Patient Volume (Absolute), 2002–2011 103
Figure   44:   Ovarian   Cancer   Therapeutics   Market,   Germany, Treatment Usage Patterns, 2002–2011 105
Figure   45:   Ovarian   Cancer   Therapeutics   Market,   Germany, Market Drivers and Restraints, 2011 107
Figure   46:   Ovarian   Cancer   Therapeutics   Market,   Germany, The Impact of Historical Events on the Market, 2011
109
Figure   47:   Ovarian   Cancer   Therapeutics   Market,   Germany,     Sales Value ($m), 2011–2020 110
Figure   48:   Ovarian   Cancer   Therapeutics   Market,   Germany,     Annual Cost of Therapy ($), 2011–2020 112
Figure   49:   Ovarian   Cancer   Therapeutics   Market,   Germany,     Patient Volume (Absolute), 2011–2020 114
Figure   50:   Ovarian   Cancer   Therapeutics   Market,   Germany,     Treatment Usage Patterns, 2011–2020 116
Figure   51:   Ovarian   Cancer   Therapeutics   Market,   Germany,     Future Market Drivers and Restraints, 2011–2020
118
Figure   52:   Ovarian   Cancer   Therapeutics   Market,   Germany, Drug Sales ($m), 2002-2020 119
Figure   53:   Ovarian   Cancer   Therapeutics   Market,   France, Sales Value ($m), 2002–2011 122
Figure   54:   Ovarian   Cancer   Therapeutics   Market,   France, Annual Cost of Therapy ($), 2002–2011 124
Figure   55:   Ovarian   Cancer   Therapeutics   Market,   France, Patient Volume (Absolute), 2002–2011 126
Figure   56:   Ovarian   Cancer   Therapeutics   Market,   France, Treatment Usage Patterns, 2002–2011 128
Figure   57:   Ovarian   Cancer   Therapeutics   Market,   France, Market Drivers and Restraints, 2011 130
Figure   58:   Ovarian   Cancer   Therapeutics   Market,   France, The Impact of Historical Events on the Market, 2011
131
Figure   59:   Ovarian   Cancer   Therapeutics   Market,   France, Sales Value ($m), 2011–2020 132
Figure   60:   Ovarian   Cancer   Therapeutics   Market,   France, Annual Cost of Therapy ($), 2011–2020 134
Figure   61:   Ovarian   Cancer   Therapeutics   Market,   France, Patient Volume (Absolute), 2011–2020 136
Figure   62:   Ovarian   Cancer   Therapeutics   Market,   France, Treatment Usage Patterns, 2011–2020 138
Figure   63:   Ovarian   Cancer   Therapeutics   Market,   France, Future Market Drivers and Restraints, 2011–2020 140
Figure   64:   Ovarian   Cancer   Therapeutics   Market,   France, Drug Sales ($m), 2002–2020 141
Figure   65:   Ovarian   Cancer   Therapeutics   Market,   Italy, Sales Value ($m), 2002–2011 144
Figure   66:   Ovarian   Cancer   Therapeutics   Market,   Italy, Annual Cost of Therapy ($), 2002–2011 146
Figure   67:   Ovarian   Cancer   Therapeutics   Market,   Italy, Patient Volume (Absolute), 2002–2011 148
Figure   68:   Ovarian   Cancer   Therapeutics   Market,   Italy, Treatment Usage Patterns, 2002–2011 150
Figure   69:   Ovarian   Cancer   Therapeutics   Market,   Italy, Market Drivers and Restraints, 2011 152
Figure   70:   Ovarian   Cancer   Therapeutics   Market,   Italy, The Impact of Historical Events on the Market, 2011 154
Figure   71:   Ovarian   Cancer   Therapeutics   Market,   Italy, Sales Value ($m), 2011–2020 155
Figure   72:   Ovarian   Cancer   Therapeutics   Market,   Italy, Annual Cost of Therapy ($), 2011–2020 157
Figure   73:   Ovarian   Cancer   Therapeutics   Market,   Italy, Patient Volume (Absolute), 2011–2020 159
Figure   74:   Ovarian   Cancer   Therapeutics   Market,   Italy, Treatment Usage Patterns, 2011–2020 161
Figure   75:   Ovarian   Cancer   Therapeutics   Market,   Italy, Future Market Drivers and Restraints, 2011–2020 163
Figure   76:   Ovarian   Cancer   Therapeutics   Market,   Italy, Drug Sales ($m), 2002-2020 164
Figure   77:   Ovarian   Cancer   Therapeutics   Market,   Spain, Sales Value ($m), 2002–2011 167
Figure   78:   Ovarian   Cancer   Therapeutics   Market,   Spain, Annual Cost of Therapy ($), 2002–2011 169
Figure   79:   Ovarian   Cancer   Therapeutics   Market,   Spain, Patient Volume (Absolute), 2002–2011 171
Figure   80:   Ovarian   Cancer   Therapeutics   Market,   Spain, Treatment Usage Patterns, 2002–2011 173
Figure   81:   Ovarian   Cancer   Therapeutics   Market,   Spain, Market Drivers and Restraints, 2011 175
Figure   82:   Ovarian   Cancer   Therapeutics   Market,   Spain, The Impact of Historical Events on the Market, 2011
177
Figure   83: Ovarian Cancer Therapeutics Market, Spain, Sales Value ($m), 2011–2020 178
Figure   84: Ovarian Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2011–2020 180
Figure   85: Ovarian Cancer Therapeutics Market, Spain, Patient Volume (Absolute), 2011–2020 182
Figure   86: Ovarian Cancer Therapeutics Market, Spain, Treatment Usage Patterns, 2011–2020 184
Figure   87: Ovarian Cancer Therapeutics Market, Spain, Future Market Drivers and Restraints, 2011–2020 186
Figure   88: Ovarian Cancer Therapeutics Market, Spain, Drug Sales ($m), 2002-2020 187
Figure   89: Ovarian Cancer Therapeutics Market, Japan, Drug Sales ($m), 2002-2011 190
Figure   90: Ovarian Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002–2011 192
Figure   91: Ovarian Cancer Therapeutics Market, Japan, Patient Volume (Absolute), 2002–2011 194
Figure   92: Ovarian Cancer Therapeutics Market, Japan, Treatment Usage Patterns, 2002–2011 196
Figure   93: Ovarian Cancer Therapeutics Market, Japan, Market Drivers and Restraints, 2011 198
Figure   94: Ovarian Cancer Therapeutics Market, Japan, Impact of Historical Events on the Market, 2011 200
Figure   95: Ovarian Cancer Therapeutics Market, Japan, Sales Value ($m), 2011–2020 201
Figure   96: Ovarian Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011–2020 203
Figure   97: Ovarian Cancer Therapeutics Market, Japan, Patient Volume (Absolute), 2011–2020 205
Figure   98: Ovarian Cancer Therapeutics Market, Japan, Treatment Usage Patterns, 2011–2020 207
Figure   99: Ovarian Cancer Therapeutics Market, Japan, Future Market Drivers and Restraints, 2011–2020 209
Figure   100: Ovarian Cancer Therapeutics Market, Japan, Drug Sales ($m), 2002-2020 210
Figure   101: Ovarian Cancer Therapeutics Market, Brazil, Sales Value ($m), 2002–2011 213
Figure   102: Ovarian Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2002–2011 215
Figure   103: Ovarian Cancer Therapeutics Market, Brazil, Patient Volume (Absolute), 2002–2011 216
Figure   104: Ovarian Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 2002–2011 218
Figure   105: Ovarian Cancer Therapeutics Market, Brazil, Market Drivers and Restraints, 2011 220
Figure   106: Ovarian Cancer Therapeutics Market, Brazil, The Impact of Historical Events on the Market, 2011
222
Figure   107:   Ovarian   Cancer   Therapeutics   Market,   Brazil, Sales Value ($m), 2011–2020 223
Figure   108:   Ovarian   Cancer   Therapeutics   Market,   Brazil, Annual Cost of Therapy ($), 2011–2020 225
Figure   109:   Ovarian   Cancer   Therapeutics   Market,   Brazil, Patient Volume (Absolute), 2011–2020 226
Figure   110:   Ovarian   Cancer   Therapeutics   Market,   Brazil, Treatment Usage Patterns, 2011–2020 228
Figure   111:   Ovarian   Cancer   Therapeutics   Market,   Brazil, Future Market Drivers and Restraints, 2011–2020 229
Figure   112:   Ovarian   Cancer   Therapeutics   Market,   Russia, Sales Value ($m), 2002–2011 230
Figure   113:   Ovarian   Cancer   Therapeutics   Market,   Russia, Annual Cost of Therapy ($), 2002–2011 231
Figure   114:   Ovarian   Cancer   Therapeutics   Market,   Russia, Patient Volume (Absolute), 2002–2011 232
Figure   115:   Ovarian   Cancer   Therapeutics   Market,   Russia, Treatment Usage Patterns, 2002–2011 234
Figure   116:   Ovarian   Cancer   Therapeutics   Market,   Russia, Market Drivers and Restraints, 2011 236
Figure   117:   Ovarian   Cancer   Therapeutics   Market,   Russia, The Impact of Historical Events on the Market, 2011
238
Figure   118:   Ovarian   Cancer   Therapeutics   Market,   Russia,   Sales Value ($m), 2011–2020 239
Figure   119:   Ovarian   Cancer   Therapeutics   Market,   Russia,   Annual Cost of Therapy ($), 2011–2020 240
Figure   120:   Ovarian   Cancer   Therapeutics   Market,   Russia,   Patient Volume (Absolute), 2011–2020 241
Figure   121:   Ovarian   Cancer   Therapeutics   Market,   Russia,   Treatment Usage Patterns, 2011–2020 243
Figure   122:   Ovarian   Cancer   Therapeutics   Market,   Russia,   Future Market Drivers and Restraints, 2011–2020
245
Figure   123:   Ovarian   Cancer   Therapeutics   Market,   India,   Sales Value ($m), 2002–2011 246
Figure   124:   Ovarian   Cancer   Therapeutics   Market,   India,   Annual Cost of Therapy ($), 2002–2011 248
Figure   125:   Ovarian   Cancer   Therapeutics   Market,   India,   Patient Volume (Absolute), 2002–2011 249
Figure   126:   Ovarian   Cancer   Therapeutics   Market,   India,   Treatment Usage Patterns, 2002–2011 251
Figure   127:   Ovarian   Cancer   Therapeutics   Market,   India,   Market Drivers and Restraints, 2011 253
Figure   128:   Ovarian   Cancer   Therapeutics   Market,   India,   The Impact of Historical Events on the Market, 2011
255
Figure   129: Ovarian Cancer Therapeutics Market, India, Sales Value ($m), 2011–2020 256
Figure   130: Ovarian Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2011–2020 258
Figure   131: Ovarian Cancer Therapeutics Market, India, Patient Volume (Absolute), 2011–2020 259
Figure 132: Ovarian Cancer Therapeutics Market, India, Treatment Usage Patterns, 2011–2020 261
Figure 133: Ovarian Cancer Therapeutics Market, India, Future Market Drivers and Restraints, 2011–2020 263
Figure 134: Ovarian Cancer Therapeutics Market, China, Sales Value ($m), 2002–2011 264
Figure 135: Ovarian Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 2002–2011 266
Figure 136: Ovarian Cancer Therapeutics Market, China, Patient Volume (Absolute), 2002–2011 267
Figure 137: Ovarian Cancer Therapeutics Market, China, Treatment Usage Patterns, 2002–2011 269
Figure 138: Ovarian Cancer Therapeutics Market, China, Market Drivers and Restraints, 2011 271
Figure 139: Ovarian Cancer Therapeutics Market, China, The Impact of Historical Events on the Market, 2011
273
Figure 140: Ovarian Cancer Therapeutics Market, China, Sales Value ($m), 2011–2020 274
Figure 141: Ovarian Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 2011–2020 276
Figure 142: Ovarian Cancer Therapeutics Market, China, Patient Volume (Absolute), 2011–2020 277
Figure 143: Ovarian Cancer Therapeutics Market, China, Treatment Usage Patterns, 2011–2020 279
Figure 144: Ovarian Cancer Therapeutics Market, China, Future Market Drivers and Restraints, 2011–2020 280
Figure 145: Ovarian Cancer, Global, Opportunity and Unmet Need in First-Line Treatment of Loco-Regional and
Advanced/Metastatic Setting, 2011 282
Figure 146: Ovarian Cancer, Global, Opportunity and Unmet Need in Second-Line Treatment of Loco-Regional
and Advanced/Metastatic Setting, 2011 283
Figure 147: Ovarian Cancer, Global, Response Rate in First-Line Loco-Regional and Advanced/Metastatic
Setting, (%), 2011 285
Figure 148: Ovarian Cancer, Global, Overall Survival in First-Line Loco-Regional and Advanced/Metastatic
Setting in Months, 2011 286
Figure 149: Ovarian Cancer, Global, Progression-free Survival in First-Line Loco-Regional and
Advanced/Metastatic Setting in Months, 2011 287
Figure 150: Ovarian Cancer, Global, Response Rate in Second-Line Loco-Regional and Advanced/Metastatic
Setting, (%) 2011 288
Figure 151: Ovarian Cancer, Global, Overall Survival in Second-Line Loco-Regional and Advanced/Metastatic
Setting, (%), 2011 289
Figure 152: Ovarian Cancer, Global, Progression-Free Survival in Second-Line Loco-Regional and
Advanced/Metastatic Setting in Months, 2011 290
Figure 153: Ovarian Cancer, Global, Time-to-Progression in Second-Line Loco-Regional and
Advanced/Metastatic Setting in Months, 2011 291
Figure 154: Strategic Competitor Assessment of the Marketed Chemotherapy Products for Ovarian Cancer,
2011 293
Figure 155: Ovarian Cancer, Global, Key Events Impacting the Future Market, 2011 294
Figure 156: Ovarian Cancer, Global, Implications for Future Market Competition, 2011 296
Figure 157: Ovarian Cancer Therapeutics Market, Global, Carboplatin, Chemical Structure, 2011 297
Figure 158: Ovarian Cancer Therapeutics Market, Global, Carboplatin, Sales Forecast ($m), 2002-2020 302
Figure 159: Ovarian Cancer Therapeutics Market, Global, Carboplatin, Market Share Analysis (%), 2011 303
Figure 160: Ovarian Cancer Therapeutics Market, Global, Cisplatin, Chemical Structure, 2011 304
Figure 161: Ovarian Cancer Therapeutics Market, Global, Cisplatin, Sales Forecast ($m), 2002–2020 306
Figure 162: Ovarian Cancer Therapeutics Market, Global, Cisplatin, Market Share Analysis (%), 2011 307
Figure 163: Ovarian Cancer Therapeutics Market, Global, Paclitaxel, Chemical Structure, 2011 308
Figure 164: Ovarian Cancer Therapeutics Market, Global, Paclitaxel, Life Cycle Management Activities, 2011
311
Figure 165: Ovarian Cancer Therapeutics Market, Global, Paclitaxel, Sales Forecast ($m), 2002-2015 312
Figure 166: Ovarian Cancer Therapeutics Market, Global, Paclitaxel, Market Share Analysis (%), 2011 313
Figure 167: Ovarian Cancer Therapeutics Market, Global, Altretamine, Chemical Structure, 2011 314
Figure 168: Ovarian Cancer Therapeutics Market, Global, Altretamine, Life Cycle Management Activities, 2011
316
Figure 169: Ovarian Cancer Therapeutics Market, Global, Hycamtin, Chemical Structure, 2011 317
Figure 170: Ovarian Cancer Therapeutics Market, Global, Hycamtin, Life Cycle Management Activities, 2011
319
Figure 171: Ovarian Cancer Therapeutics Market, Global, Hycamtin, Sales Forecast ($m), 2002–2015 320
Figure 172: Ovarian Cancer Therapeutics Market, Global, Hycamtin, Market Share Analysis (%), 2011 321
Figure 173: Ovarian Cancer Therapeutics Market, Global, Gemzar, Chemical Structure, 2011 322
Figure 174: Ovarian Cancer Therapeutics Market, Global, Gemzar, Life Cycle Management Activities, 2011 324
Figure 175: Ovarian Cancer Therapeutics Market, Global, Gemzar, Sales Forecast ($m), 2004–2015 325
Figure 176: Ovarian Cancer Therapeutics Market, Global, Gemzar, Market Share Analysis (%), 2011 326
Figure 177: Ovarian Cancer Therapeutics Market, Global, Yondelis, Chemical Structure, 2011 327
Figure 178: Ovarian Cancer Therapeutics Market, Global, Yondelis, Life Cycle Management Activities, 2011 329
Figure 179: Ovarian Cancer Therapeutics Market, Global, Yondelis, Sales Forecast ($m), 2009–2020 329
Figure 180: Ovarian Cancer Therapeutics Market, Global, Yondelis, Market Share Analysis (%), 2011 330
Figure 181: Ovarian Cancer Therapeutics Market, Global, Doxil, Chemical Structure, 2011 331
Figure 182: Ovarian Cancer Therapeutics Market, Global, Doxil, Life Cycle Management Activities, 2011 333
Figure 183: Ovarian Cancer Therapeutics Market, Global, Doxil, Sales Forecast ($m), 2002-2016 334
Figure 184: Ovarian Cancer Therapeutics Market, Global, Doxil, Market Share Analysis (%), 2011 335
Figure 185: Ovarian Cancer, Global, Clinical Trials by Phase of Development, 2011 337
Figure 186: Ovarian Cancer, Global, Pipeline by Mechanism of Action, 2011 338
Figure 187: Ovarian Cancer, Global, Pipeline by Line of Therapy, 2011 339
Figure 188: Ovarian Cancer, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2011 341
Figure 189: Ovarian Cancer, Global, Technology Trends Description of Pipeline Drugs, 2011 341
Figure 190: Ovarian Cancer Pipeline by Phase of Clinical Development, 2011 342
Figure 191: Ovarian Cancer Therapeutics Market, Global, Avastin Sales Forecasts ($m), 2012-2020 353
Figure 192: Ovarian Cancer Therapeutics Market, Global, Paclical Sales Forecast ($m), 2012–2020 355
Figure 193: Ovarian Cancer Therapeutics Market, Global, Votrient Sales Forecast ($m), 2013–2020 357
Figure 194: Ovarian Cancer Therapeutics Market, Global, Farletuzumab Sales Forecast ($m), 2014-2020 359
Figure 195: Ovarian Cancer Therapeutics Market, Global, Karenitecin Sales Forecast ($m), 2014-2020 361
Figure 196: Ovarian Cancer Therapeutics Market, The US, Opaxio Sales Forecast ($m), 2014-2020 363
Figure 197: Ovarian Cancer Therapeutics Market, Global, AMG 386 Sales Forecast ($m), 2015–2020 365
Figure 198: Ovarian Cancer Therapeutics Market, Global, EC145 Sales Forecast ($m), 2016–2020 366
Figure 199: Ovarian Cancer Therapeutics Market, Global, Recentin Sales Forecast ($m), 2015–2020 368
Figure 200: Ovarian Cancer Therapeutics Market, Global, Vargatef Sales Forecast ($m), 2017-2020 370
Figure 201: Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Status, March 2011 376
Figure 202: Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Country, March 2011 377
Figure 203: Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Phase, March 2011 378
Figure 204: Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, March 2011 379
Figure 205: Ovarian Cancer Therapeutics Market, Global, Clinical Trials, Leading Sponsors, March 2011 380
Figure 206: Ovarian Cancer Therapeutics Market, Global, Clinical Trials, Leading Company Sponsors, March
2011 381
Figure 207: Ovarian Cancer Therapeutics Market, Global, Clinical Trials, Average Number of Patients Recruited,
March 2011 382
Figure 208: Ovarian Cancer, F. Hoffmann-La Roche Ltd., SWOT Analysis 2011 384
Figure 209: Ovarian Cancer, Menarini Group, SWOT Analysis 2011 390
Figure 210: Ovarian Cancer, Global, GlaxoSmithKline, SWOT Analysis 2011 395
Figure 211: Ovarian Cancer, Eisai Inc., SWOT Analysis 2011 401
Figure 212: Ovarian Cancer, Cell Therapeutics, Inc., SWOT Analysis 2011 405
Figure 213: Ovarian Cancer, Amgen Inc., SWOT Analysis 2011 410
Figure 214: Ovarian Cancer, Global, AstraZeneca, SWOT Analysis 2011 415
Figure 215: Ovarian Cancer, Boehringer Ingelheim GmbH, SWOT Analysis 2011 420
Figure 216: Ovarian Cancer, Global, Key Data Inputs from KOL Interviews, 2011 427
Figure 217: Company Market Forecasting Model 435

Company Mentioned:


F. Hoffmann-La Roche Ltd.
Menarini Group
GlaxoSmithKline plc.
Eisai Inc.,
Cell Therapeutics, Inc.
Amgen Inc.
AstraZeneca PLC
Boehringer Ingelheim GmbH
Oasmia Pharmaceutical AB
Endocyte, Inc.
BioNumerik Pharmaceuticals, Inc.


If you would like to order:


Product name: Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020

           http://www.aarkstore.com/reports/Ovarian-Cancer-Therapeutics-Global-Drug-
Product link:
Forecasts-and-Treatment-Analysis-2020-198870.html

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
contact@aarkstore.com
Payment


To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'ORDER NOW' button


http://www.aarkstore.com/reports/Ovarian-Cancer-Therapeutics-Global-Drug-Forecasts-and-
Treatment-Analysis-2020-198870.html

To pay by Wire Transfer, please, fill in your contact details in the form below:


First name:


Last name:


E-mail:


Company:


Address:


City:


Zip/Post Code:


Country:


Tel:


Fax:


Your message:




Customer Signature _______________________________________



These Below keywords provides the latest, highly detailed information :-
Chemicals, Energy & Resources, Pharmaceuticals & Healthcare, Medical, Nuclear Energy, Mining, Power, Metals
& Mining, Alternative Energy